Comment from The Cure Coalition

Summary: The Cure Coalition supports the FDA's efforts to streamline nonclinical safety studies for oncology therapeutics and reduce unnecessary animal use. However, they recommend strengthening the guidance by requiring explicit validation of new approach methodologies (NAMs), defining minimum evidentiary standards for weight-of-evidence (WoE) packages, and ensuring that streamlined approaches remain the exception rather than the default for high-risk products.